SG11202103509RA - Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof - Google Patents

Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof

Info

Publication number
SG11202103509RA
SG11202103509RA SG11202103509RA SG11202103509RA SG11202103509RA SG 11202103509R A SG11202103509R A SG 11202103509RA SG 11202103509R A SG11202103509R A SG 11202103509RA SG 11202103509R A SG11202103509R A SG 11202103509RA SG 11202103509R A SG11202103509R A SG 11202103509RA
Authority
SG
Singapore
Prior art keywords
aoah
genetically
stem cells
mesenchymal stem
cells overexpressing
Prior art date
Application number
SG11202103509RA
Other languages
English (en)
Inventor
Michael Callahan
Shirley H J Mei
Yan Wang
Maria Florian
Katelynn Rowe
Chyan-Jang Lee
Original Assignee
Ottawa Hospital Res Inst
United Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ottawa Hospital Res Inst, United Therapeutics Corp filed Critical Ottawa Hospital Res Inst
Publication of SG11202103509RA publication Critical patent/SG11202103509RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01077—Acyloxyacyl hydrolase (3.1.1.77)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202103509RA 2018-10-29 2019-10-29 Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof SG11202103509RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862752000P 2018-10-29 2018-10-29
PCT/CA2019/051526 WO2020087160A1 (en) 2018-10-29 2019-10-29 Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof

Publications (1)

Publication Number Publication Date
SG11202103509RA true SG11202103509RA (en) 2021-05-28

Family

ID=70462996

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103509RA SG11202103509RA (en) 2018-10-29 2019-10-29 Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof

Country Status (10)

Country Link
US (1) US20220010281A1 (enExample)
EP (1) EP3874029B1 (enExample)
JP (1) JP7372982B2 (enExample)
KR (1) KR20210086662A (enExample)
CN (1) CN113166729A (enExample)
AU (1) AU2019370629A1 (enExample)
ES (1) ES2962812T3 (enExample)
IL (1) IL282820A (enExample)
SG (1) SG11202103509RA (enExample)
WO (1) WO2020087160A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021360131A1 (en) * 2020-10-16 2023-05-25 Ottawa Hospital Research Institute Cell-based therapy for viral diseases
CN116570711A (zh) * 2022-12-21 2023-08-11 上海交通大学医学院附属第九人民医院 酰基羧酸水解酶在制备治疗肾脏纤维化疾病的药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
US5281520A (en) * 1990-09-12 1994-01-25 Zymogenetics, Inc. Method for producing acyloxyacyl hydrolase
CN101378764A (zh) * 2005-12-09 2009-03-04 贝勒研究院 通过血液白细胞微阵列分析对系统性红斑狼疮的诊断、预后和疾病发展的监测
AU2009275135A1 (en) * 2008-07-21 2010-01-28 Compugen Ltd. Angiopoietin derived peptides
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
BRPI1015179A2 (pt) * 2009-06-19 2016-04-19 Merck Patent Gmbh biomarcadores e métodos para a determinação de eficácia de anticorpos anti-egfr em terapia de câncer
EP2626369A1 (en) * 2011-11-24 2013-08-14 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Engineered mesenchymal stem cells and their therapeutic use
CA2859452C (en) * 2012-03-27 2021-12-21 Curevac Gmbh Artificial nucleic acid molecules for improved protein or peptide expression
WO2013151663A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
AU2014342162B2 (en) * 2013-11-01 2020-01-02 Regeneron Pharmaceuticals, Inc. Angiopoietin-based interventions for treating cerebral malaria
EP3087101B1 (en) * 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
NZ727950A (en) * 2014-06-30 2022-07-01 Takeda Pharmaceuticals Co Mesenchymal stromal cells for treating sepsis
LT3242933T (lt) * 2015-01-08 2019-06-25 Apceth Gmbh & Co. Kg Genetiškai modifikuotos mezenchiminės kamieninės ląstelės, ekspresuojančios alfa-1 antitripsiną (aat)
JP7269733B2 (ja) * 2015-06-12 2023-05-09 レンティジェン・テクノロジー・インコーポレイテッド 操作されたｔ細胞を用いて癌を処置するための方法
EP3351254A4 (en) * 2015-09-15 2019-07-17 Kangstem Biotech Co., Ltd. COMPOSITION FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES WITH SOD3 OVEREXPRIMATING STEM CELLS AS AN ACTIVE SUBSTANCE

Also Published As

Publication number Publication date
WO2020087160A1 (en) 2020-05-07
JP2022513379A (ja) 2022-02-07
AU2019370629A1 (en) 2021-05-20
EP3874029A1 (en) 2021-09-08
IL282820A (en) 2021-06-30
CN113166729A (zh) 2021-07-23
US20220010281A1 (en) 2022-01-13
EP3874029A4 (en) 2022-08-03
EP3874029B1 (en) 2023-08-30
CA3116196A1 (en) 2020-05-07
KR20210086662A (ko) 2021-07-08
JP7372982B2 (ja) 2023-11-01
ES2962812T3 (es) 2024-03-21

Similar Documents

Publication Publication Date Title
IL287553A (en) Modified pluripotent cells
IL285619A (en) Universal donor stem cells and related methods
IL277025A (en) Methods for improving the differentiation of stem cells into beta cells
SG11202101994XA (en) Genetically engineered hematopoietic stem cells and uses thereof
IL267616A (en) Immunologically engineered pluripotent cells
IL275037A (en) CRISPR-CAS9-modified CD34+ human hematopoietic stem and progenitor cells and uses thereof
IL281171A (en) Cellulose-synthase-like enzymes and their uses
SG10201705182RA (en) Method of distinguishing mesenchymal stem cells and method of determining purity of mesenchymal stem cells
GB201819540D0 (en) T cell modification
IL263265A (en) Use of mesenchymal stem cells and their parts
EP3866816A4 (en) EXOSOMES FROM MESENCHYMATOUS STEM CELLS AND METHODS
SG11202107732XA (en) Dorsally-derived oligodendrocyte progenitor cells from human pluripotent stem cells
IL255480B (en) Preparations containing mesenchymal stem cells and their uses
ES2948810T8 (en) Method for obtaining an enriched population of functional mesenchymal stem cells, cells obtained thereof and compositions comprising the same
EP4034172A4 (en) GENETICALLY MODIFIED MESENCHYMATOUS STEM CELLS AND THEIR APPLICATIONS
IL268194B (en) Environment and methods to increase survival and proliferation of embryo cells
IL253063A0 (en) Genetically modified mesenchymal stem cells expressing alpha-1 antitrypsin (aat)
EP3886880C0 (en) METHODS AND APPARATUS FOR OBTAINING AMNIOTIC MESENCHYMATOUS STEM CELLS FROM AMNIOTIC FLUID AND CELLS DERIVED THEREOF
IL281153A (en) Direct differentiation of a urinary cell into a neural stem cell using artificial mRNA
GB201701509D0 (en) Pluripotenet stem cells
SG11202005509YA (en) Recombinant adenoviruses and stem cells comprising same
IL290109A (en) Cells for enhanced immune healing and their uses
EP3865571C0 (en) SYNOVIAL-DERIVED MESENCHYMAL STEM CELLS AND THEIR USE
IL281751A (en) Methods for inducing differentiation in mesenchymal stem cells
IL282820A (en) Genetically engineered embryonic mesenchymal cells overexpressing AOAH and their uses